Focal Healthcare Announces FDA and Health Canada Clearance
Focal Healthcare (OBIO Pre-CAAP 2015) announced it has received both FDA 510(k) clearance and Health Canada approval for its Fusion Bx™ 2.0 prostate biopsy solution, which is now available for sale in the United States and Canada.